MorphoSys AG Reports First Quarter 2023 Financial Results :

Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline

Related Keywords

Massachusetts , United States , Boston , Planegg , Bayern , Germany , Canada , United Kingdom , American , Charlotte Lohmann , Jean Paul Kress , Thomas Biegi , Lucinda Crabtree , Monjuvi Minjuvi , Julia Neugebauer , Eamonn Nolan , American Association For Cancer Research , Janssen Biotech Inc , Morphosys Group Key Figures , Nasdaq , Exchange Commission , Drug Administration , American Society Of Clinical Oncology , Twitter , Share Of Loss Associates , Xencor Inc , Linkedin , Development Rd Expenses , Chief Executive Officer , Chief Financial Officer , Management Board , Chief Legal Officer , Morphosy Management Board , Events After , First Quarter , Data Highlight , American Association , Cancer Research , Annual Meeting , Clinical Oncology , Net Loss , Sys Group Key Figures , Impairment Losses , Equity Method , Tax Benefit , Net Profit , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Janssen Biotech , Looking Statements , Morphosy Annual Report , Investor Relations , Morphosys , Reports , First , Quarter , 023 , Financial , Results ,